Neurocrine Biosciences
NBIX

$120.17

0.86%

Market Cap: $12.1B

About: Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Employees: 1,500

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 18 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

134% more call options, than puts

Call options by funds: $125M | Put options by funds: $53.6M

34% more repeat investments, than reductions

Existing positions increased: 249 | Existing positions reduced: 186

7% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 73

1% more funds holding

Funds holding: 576 [Q1] → 581 (+5) [Q2]

2% less capital invested

Capital invested by funds: $13.1B [Q1] → $12.9B (-$207M) [Q2]

2.4% less ownership

Funds ownership: 95.47% [Q1] → 93.07% (-2.4%) [Q2]

11% less funds holding in top 10

Funds holding in top 10: 9 [Q1] → 8 (-1) [Q2]

See Fund Rankings

Research analyst outlook

18 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$128

7%

upside

Avg. target

$169

41%

upside

High target

$219

82%

upside

18 analyst ratings

14 positive

78%

4 neutral

22%

0 negative

0%

Cantor Fitzgerald Charles Duncan 47% 1-year accuracy 32 / 68 met price target	29%upside $155	Overweight Maintained	29 Aug 2024
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target	13%upside $136	Sector Perform Maintained	29 Aug 2024
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target	58%upside $190	Buy Reiterated	29 Aug 2024
Piper Sandler David Amsellem 61% 1-year accuracy 22 / 36 met price target	32%upside $159	Overweight Upgraded	29 Aug 2024
BMO Capital Evan Seigerman 69% 1-year accuracy 9 / 13 met price target	7%upside $128	Market Perform Maintained	29 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about NBIX published over the past 30 days

The Motley Fool

Why Neurocrine Biosciences Stock Was Tumbling This Week

The biotech released the results of phase 2 clinical trial of its investigational schizophrenia drug. One of the four doses clearly performed well.

Why Neurocrine Biosciences Stock Was Tumbling This Week

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock

Wednesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock

Zacks Investment Research

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Despite Neurocrine Biosciences, Inc. muscarinic receptor drug NBI-'568 not surpassing competitors in Schizophrenia, several other drugs of the same type are being developed for large market indications like Alzheimer's Disease. There are several other shots on goal in targeting the Schizophrenia patient populations using luvadaxistat and others. The global Schizophrenia Drugs Market is forecasted to reach $9.46 billion by 2030.

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Neurocrine Biosciences to Participate at Investor Conferences in September

Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at two upcoming investor conferences in September. Chief Executive Officer Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and Chief Financial Officer Matt Abernethy will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York at 3:20 p.m.

Neurocrine Biosciences to Participate at Investor Conferences in September

Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard

Neurocrine Biosciences posted disappointing Phase II data for its schizophrenia drug NBI-1117568, driving a steep fall in the share price. NBI-568 came up short in terms of PANSS reduction, with a 7.5pt placebo-adjusted reduction missing the double-digit target the Street wanted to see. Management remains optimistic about '568, planning Phase III trials, but it seems optimistic to think that Phase III results are likely to be good enough to make '568 truly competitive.

Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

Investors Business Daily

Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers

As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial.

Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers

Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Tokyo, Japan and Cambridge, UK, 28 August 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that NBI-1117568 (NBI-‘568) has delivered positive topline results from its Phase 2 clinical study in adults with schizophrenia. NBI-'568 is the first investigational, oral, muscarinic M4 selective agonist in development for the treatment of schizophrenia.

Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Neurocrine's schizophrenia drug meets main goal in mid-stage study

Neurocrine Biosciences said on Wednesday its experimental drug to treat adults with schizophrenia met the main goal in a mid-stage study.

Neurocrine's schizophrenia drug meets main goal in mid-stage study

See News Rankings